Sunstone Life Science Fund II portfolio company Orphazyme has announced that the FDA has granted Fast Track designation for the investigation of arimoclomol intended for the treatment of Niemann-Pick disease type C. The FDA’s Fast Track Program is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. “The Fast Track designation is really good news for everyone involved in the AIDNPC trial, not least the sufferers of Niemann-Pick disease type C who deserve that every effort is made to expedite development of promising new therapies”, says Orphazyme ApS CEO Anders Hinsby.